{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:48:18Z","timestamp":1791215298662,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":599,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004072","name":"Kiadis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016477","name":"CareDx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016477","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008980","name":"Medical College of Wisconsin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["HHSH250201700006C"],"award-info":[{"award-number":["HHSH250201700006C"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["N00014-20-1-2705"],"award-info":[{"award-number":["N00014-20-1-2705"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["N00014-20-1-2832"],"award-info":[{"award-number":["N00014-20-1-2832"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"Office of Naval Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jtct.2021.06.028","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T12:28:40Z","timestamp":1625228920000},"page":"837.e1-837.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies"],"prefix":"10.1016","volume":"27","author":[{"given":"Wael","family":"Saber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Steinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Wingard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ballen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Stiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Langston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Rudebeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.06.028_bib0001","first-page":"89","article-title":"Efficacy of palifermin in the hematopoietic stem cell transplant setting","volume":"4","author":"Panjwani","year":"2013","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.jtct.2021.06.028_bib0002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1191\/1078155205jp159oa","article-title":"Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support","volume":"11","author":"Radtke","year":"2005","journal-title":"J Oncol Pharm Pract"},{"issue":"6 suppl 18)","key":"10.1016\/j.jtct.2021.06.028_bib0003","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.seminoncol.2003.11.040","article-title":"The effect of oral mucositis on morbidity and mortality in bone marrow transplant","volume":"30","author":"Gabriel","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtct.2021.06.028_bib0004","first-page":"400","article-title":"Oral complications of cancer and cancer therapy: from cancer treatment to survivorship","volume":"62","author":"Epstein","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"9 suppl","key":"10.1016\/j.jtct.2021.06.028_bib0005","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/cncr.20162","article-title":"Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients","volume":"100","author":"Sonis","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2021.06.028_bib0006","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/CCO.0000000000000180","article-title":"Mucositis: pathobiology and management","volume":"27","author":"Villa","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jtct.2021.06.028_bib0007","doi-asserted-by":"crossref","first-page":"lgz010","DOI":"10.1093\/jncimonographs\/lgz010","article-title":"Costs of oral complications of cancer therapies: estimates and a blueprint for future study","volume":"2019","author":"Elting","year":"2019","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.jtct.2021.06.028_bib0008","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/cncr.28592","article-title":"MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","volume":"120","author":"Lalla","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2021.06.028_bib0009","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/vox.12835","article-title":"Granulocyte transfusions could benefit patients with severe oral mucositis after allogeneic hematopoietic stem cell transplantation","volume":"114","author":"Berglund","year":"2019","journal-title":"Vox Sang"},{"key":"10.1016\/j.jtct.2021.06.028_bib0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SPC.0000000000000310","article-title":"Advances in the understanding and management of mucositis during stem cell transplantation","volume":"11","author":"Bowen","year":"2017","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.jtct.2021.06.028_bib0011","first-page":"7379","article-title":"Palifermin in children undergoing autologous stem cell transplantation: a matched-pair analysis","volume":"34","author":"Czyzewski","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtct.2021.06.028_bib0012","first-page":"343","article-title":"Palifermin and chlorhexidine mouthwashes in prevention of chemotherapy-induced mucositis in children with acute lymphocytic leukemia: a randomized controlled trial","volume":"17","author":"Gholizadeh","year":"2016","journal-title":"J Dent (Shiraz)"},{"key":"10.1016\/j.jtct.2021.06.028_bib0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ijos.2013.93","article-title":"Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case-control study","volume":"6","author":"Lauritano","year":"2014","journal-title":"Int J Oral Sci"},{"key":"10.1016\/j.jtct.2021.06.028_bib0014","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1097\/MPH.0000000000000791","article-title":"Retrospective evaluation of palifermin use in nonhematopoietic stem cell transplant pediatric patients","volume":"39","author":"Liu","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2021.06.028_bib0015","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2016.02.016","article-title":"Safety, pharmacokinetics, and efficacy of palifermin in children and adolescents with acute leukemias undergoing myeloablative therapy and allogeneic hematopoietic stem cell transplantation: a Pediatric Blood and Marrow Transplant Consortium Trial","volume":"22","author":"Morris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.028_bib0016","first-page":"3141","article-title":"Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation","volume":"23","author":"Nguyen","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jtct.2021.06.028_bib0017","article-title":"Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors","volume":"11","author":"Riley","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtct.2021.06.028_bib0018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/bmjspcare-2014-000804","article-title":"Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation","volume":"7","author":"Sung","year":"2017","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.jtct.2021.06.028_bib0019","first-page":"43","article-title":"Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial","volume":"65","author":"Lucchese","year":"2016","journal-title":"Minerva Stomatol"},{"key":"10.1016\/j.jtct.2021.06.028_bib0020","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1056\/NEJMoa040125","article-title":"Palifermin for oral mucositis after intensive therapy for hematologic cancers","volume":"351","author":"Spielberger","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.06.028_bib0021","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3109\/10428194.2015.1081192","article-title":"Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia","volume":"57","author":"Lucchese","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2021.06.028_bib0022","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.bbmt.2008.06.013","article-title":"Long-term follow-up of a phase I\/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT)","volume":"14","author":"Levine","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.028_bib0023","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1182\/blood-2006-04-017780","article-title":"Phase 1\/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)","volume":"108","author":"Blazar","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.06.028_bib0024","first-page":"4011","article-title":"Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines","volume":"27","author":"Bowen","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jtct.2021.06.028_bib0025","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/bmt.2014.140","article-title":"Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa","volume":"49","author":"Milone","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.028_bib0026","unstructured":"Swedish Orphan Biovitrum. Kepivance\u00ae (palifermin). Highlights of prescribing information. Available at: https:\/\/sobi-northamerica.com\/sites\/default\/files\/2018-06\/Kepivance%20PI%20USA.pdf. Published 2020. Accessed March 16, 2021."},{"key":"10.1016\/j.jtct.2021.06.028_bib0027","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbmt.2015.08.018","article-title":"Long-term safety outcomes in patients with hematological malignancies undergoing autologous hematopoietic stem cell transplantation treated with palifermin to prevent oral mucositis","volume":"22","author":"Stiff","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.028_bib0028","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.bbmt.2016.04.008","article-title":"The impact of palifermin use on hematopoietic cell transplant outcomes in children","volume":"22","author":"Saber","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.028_bib0029","unstructured":"Center for International Blood and Marrow Transplant Research. CIBMTR 2020 annual report. Available at: https:\/\/www.cibmtr.org\/About\/AdminReports\/Documents\/2020CIBMTRAnnualReport.pdf. Accessed February 1, 2021."},{"key":"10.1016\/j.jtct.2021.06.028_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.jtct.2021.06.028_bib0031","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","article-title":"Reducing bias in observational studies using subclassification on the propensity score","volume":"79","author":"Rosenbaum","year":"1984","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jtct.2021.06.028_bib0032","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","article-title":"Constructing a control group using multivariate matched sampling methods that incorporate the propensity score","volume":"39","author":"Rosenbaum","year":"1985","journal-title":"Am Stat"},{"key":"10.1016\/j.jtct.2021.06.028_bib0033","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(02)08272-7","article-title":"Quantification of the completeness of follow-up","volume":"359","author":"Clark","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2021.06.028_bib0034","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djj228","article-title":"Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors","volume":"98","author":"Finch","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtct.2021.06.028_bib0035","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1158\/1541-7786.MCR-07-2131","article-title":"Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models","volume":"6","author":"Brake","year":"2008","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.jtct.2021.06.028_bib0036","unstructured":"American Society for Blood and Marrow Transplantation (ASBMT). ASBMT RFI 2017 - Disease classifications corresponding to CIBMTR classifications. Available at: https:\/\/higherlogicdownload.s3.amazonaws.com\/ASBMT\/43a1f41f-55cb-4c97-9e78-c03e867db505\/UploadedImages\/ASBMT_RFI_2018B_CIBMTR_Disease_Classifications.pdf. Published 2017. Updated February 20, 2017. Accessed March 12 , 2021."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721010319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721010319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:07:42Z","timestamp":1763003262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721010319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2666636721010319"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.06.028","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}